While patients with SHTG have an elevated risk for CV events, the primary clinical risk in patients with TG ≥ 500 mg dl−1 is acute pancreatitis, owing to saturation of, or impairment in, lipoprotein lipase-mediated lipolysis. The gene discussed is LPL; the disease is acute pancreatitis.